Clinical Trials
18 trialsNCT01933932 2025-11-19
SELECT-1
AstraZeneca
Phase 3 Active not recruiting
NCT03036488 2025-10-29
MK-3475-522
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03102606 2024-08-29
Protective-1
BeyondSpring Pharmaceuticals Inc.
Phase 3 Completed
NCT03197935 2023-10-26
IMpassion031
Hoffmann-La Roche
Phase 3 Completed
NCT03252431 2023-07-03
Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 3 Completed
NCT01126190 2023-03-28
NEUGR-003
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3 Completed
NCT02643420 2022-03-02
ADVANCE
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT02953340 2022-03-02
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT02467868 2022-02-14
Efficacy and Safety Study With MYL-1401H and Neulasta
Viatris Inc.
Phase 3 Completed
NCT03294577 2021-01-15
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
BeyondSpring Pharmaceuticals Inc.
Phase 3 Unknown
NCT03404752 2018-01-19
Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.
Gema Biotech S.A.
Phase 3 Unknown
NCT03381417 2018-01-02
Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Phase 3 Completed
NCT00911170 2017-12-29
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Amgen
Phase 3 Completed
NCT01516736 2017-08-30
PROTECT2
Sandoz
Phase 3 Completed
NCT01735175 2017-08-07
PROTECT-1
Sandoz
Phase 3 Completed
NCT01519700 2015-05-06
PIONEER
Sandoz
Phase 3 Completed
NCT00035594 2013-05-09
Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy
Amgen
Phase 3 Completed
NCT00117910 2008-05-16
Treatment for Elderly Patients With High Risk Breast Cancer
Amgen
Phase 3 Completed